Precigen
PGEN • NASDAQ
Precigen is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Helen Sabzevari, with a market cap of $1.3B.
CEOHelen Sabzevari
Next Earnings
Upcoming earnings announcement for Precigen
Date
Wednesday, May 13, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.08
Revenue Estimate
$17.8M
Earnings History
Past 12 earnings reports for Precigen
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | Q4 2025 | -$0.01Est: -$0.09 | +88.9% | $4.6MEst: $7.2M | -36.5% | — |
| Nov 13, 2025 | Q3 2025 | -$1.06Est: -$0.09 | -1077.8% | $2.9MEst: $500.0K | +484.4% |  10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.09Est: -$0.09 | 0.0% | $856.0KEst: $960.0K | -10.8% | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.18Est: -$0.08 | -125.0% | $1.3MEst: $500.0K | +168.2% | 10-Q |
| Mar 19, 2025 | Q4 2024 | -$0.06Est: -$0.06 | 0.0% | $1.2MEst: $1.2M | -3.3% | 10-K/A |
| Nov 14, 2024 | Q3 2024 | -$0.09Est: -$0.08 | -12.5% | $953.0KEst: $1.3M | -23.8% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.23Est: -$0.09 | -155.6% | $717.0KEst: $1.3M | -44.0% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.10Est: -$0.09 | -11.1% | $1.1MEst: $1.5M | -28.0% | 10-Q |
| Mar 19, 2024 | Q4 2023 | -$0.13Est: -$0.08 | -62.5% | $1.2MEst: $1.7M | -27.8% | 10-K/A |
| Nov 9, 2023 | Q3 2023 | -$0.08Est: -$0.08 | 0.0% | $1.4MEst: $2.0M | -30.4% | — |
| Aug 9, 2023 | Q2 2023 | -$0.08Est: -$0.10 | +20.0% | $1.8MEst: $2.2M | -18.9% | — |
| May 10, 2023 | Q1 2023 | -$0.10Est: -$0.09 | -11.1% | $1.9MEst: $2.2M | -16.6% | — |